vs
Side-by-side financial comparison of Aspire Biopharma Holdings, Inc. (ASBP) and XBiotech Inc. (XBIT). Click either name above to swap in a different company.
Aspire Biopharma Holdings, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapeutic candidates for unmet needs in oncology and rare diseases, with primary operations across North America and key Asia-Pacific markets.
XBiotech Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas. It specializes in the research and development of human-derived antibody therapeutics for multiple diseases, including cancer, rheumatological, and infectious diseases.
ASBP vs XBIT — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $1.9K | $0 |
| Net Profit | $-1.9M | $-4.6M |
| Gross Margin | 45.5% | — |
| Operating Margin | -59015.8% | — |
| Net Margin | -95337.1% | — |
| Revenue YoY | — | — |
| Net Profit YoY | -755.6% | -44.7% |
| EPS (diluted) | $-0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $1.9K | — | ||
| Q4 23 | — | $0 | ||
| Q3 23 | — | $0 | ||
| Q2 23 | — | $0 | ||
| Q1 23 | — | $0 | ||
| Q4 22 | — | $300.0K | ||
| Q3 22 | — | $1.7M | ||
| Q2 22 | — | $1.5M |
| Q3 25 | $-1.9M | — | ||
| Q4 23 | — | $-4.6M | ||
| Q3 23 | — | $-7.4M | ||
| Q2 23 | — | $-8.7M | ||
| Q1 23 | — | $-3.8M | ||
| Q4 22 | — | $-3.2M | ||
| Q3 22 | — | $-12.7M | ||
| Q2 22 | — | $-11.6M |
| Q3 25 | 45.5% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | 94.7% | ||
| Q3 22 | — | 87.2% | ||
| Q2 22 | — | 86.5% |
| Q3 25 | -59015.8% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | -2720.7% | ||
| Q3 22 | — | -380.3% | ||
| Q2 22 | — | -790.5% |
| Q3 25 | -95337.1% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | -1067.7% | ||
| Q3 22 | — | -753.5% | ||
| Q2 22 | — | -761.0% |
| Q3 25 | $-0.04 | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $200.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-11.5M | $218.8M |
| Total Assets | $2.4M | $226.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q4 23 | — | $200.0M | ||
| Q3 23 | — | $202.2M | ||
| Q2 23 | — | $204.8M | ||
| Q1 23 | — | $212.7M | ||
| Q4 22 | — | $217.5M | ||
| Q3 22 | — | $220.1M | ||
| Q2 22 | — | $225.8M |
| Q3 25 | $-11.5M | — | ||
| Q4 23 | — | $218.8M | ||
| Q3 23 | — | $222.7M | ||
| Q2 23 | — | $229.1M | ||
| Q1 23 | — | $236.9M | ||
| Q4 22 | — | $240.4M | ||
| Q3 22 | — | $244.8M | ||
| Q2 22 | — | $255.8M |
| Q3 25 | $2.4M | — | ||
| Q4 23 | — | $226.6M | ||
| Q3 23 | — | $229.6M | ||
| Q2 23 | — | $235.1M | ||
| Q1 23 | — | $242.1M | ||
| Q4 22 | — | $246.1M | ||
| Q3 22 | — | $250.8M | ||
| Q2 22 | — | $266.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-3.4M |
| Free Cash FlowOCF − Capex | — | $-3.5M |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-19.1M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-1.1M | — | ||
| Q4 23 | — | $-3.4M | ||
| Q3 23 | — | $-1.5M | ||
| Q2 23 | — | $-9.0M | ||
| Q1 23 | — | $-4.8M | ||
| Q4 22 | — | $-3.2M | ||
| Q3 22 | — | $-1.1M | ||
| Q2 22 | — | $-5.4M |
| Q3 25 | — | — | ||
| Q4 23 | — | $-3.5M | ||
| Q3 23 | — | $-1.5M | ||
| Q2 23 | — | $-9.2M | ||
| Q1 23 | — | $-4.8M | ||
| Q4 22 | — | $-3.3M | ||
| Q3 22 | — | $-1.4M | ||
| Q2 22 | — | $-5.5M |
| Q3 25 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | -1098.7% | ||
| Q3 22 | — | -81.0% | ||
| Q2 22 | — | -357.5% |
| Q3 25 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | 44.0% | ||
| Q3 22 | — | 12.5% | ||
| Q2 22 | — | 5.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
